Clinical Trial Update: Measurement of Hormone Levels in Patients Receiving 17-HPC for Preterm Delivery

View source ↗

Summary

A completed clinical trial investigates how hormone levels change in patients receiving 17-hydroxyprogesterone caproate to prevent preterm birth.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preterm Birth

Drugs mentioned

• Makena (hydroxyprogesterone caproate)

Snippet

Sponsor: Georgetown University | Conditions: Preterm Delivery | Status: COMPLETED